Furthermore, high expression of mesothelin was correlated with poor prognosis in several human cancers [22–24], and in pancreatic cancer, the coexpression of MUC16 and mesothelin was reported to be an independent prognostic factor for poor prognosis [12]. Here, MSLN is linked to cancer.